Zhang WH - Search Results

1

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, Weng DS, Xu X, Li YZ, Tang Y, Zhang WH, Li JY, Zheng X, Wang QJ, Li YQ, Xiang T, Zhou L, Yang SN, Wu C, Huang RX, He J, Du WJ, Chen LJ, Wu YN, Xu B, Shen Q, Zhang Y, Jiang JT, Ren XB, Xia JC. Pan QZ, et al. Among authors: zhang ds, zhang wh, zhang y. Signal Transduct Target Ther. 2024 Apr 3;9(1):79. doi: 10.1038/s41392-024-01788-2. Signal Transduct Target Ther. 2024. PMID: 38565886 Free PMC article. Clinical Trial.

2

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Zhou L, Xiong Y, Wang Y, Meng Y, Zhang W, Shen M, Zhang X, Li S, Ren B, Li R, Han Y, Zhang J, Cao S, Du W, Sun Q, Wei F, An X, Yang L, Zhang Y, Ma W, Xu W, Zhang Y, Jiang J, Xu X, Xia J, Liu L, Ren X. Zhou L, et al. Clin Lung Cancer. 2022 Dec;23(8):709-719. doi: 10.1016/j.cllc.2022.07.009. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 35995696 Free article. Clinical Trial.

3

[Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].

Wang X, Zhang W, Du W, Zhang X, Ren X, Cao S. Wang X, et al. Zhongguo Fei Ai Za Zhi. 2017 Nov 20;20(11):761-768. doi: 10.3779/j.issn.1009-3419.2017.11.07. Zhongguo Fei Ai Za Zhi. 2017. PMID: 29167006 Free PMC article. Chinese.

4

Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.

Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB. Li H, et al. Cytotherapy. 2009;11(8):1076-83. doi: 10.3109/14653240903121252. Cytotherapy. 2009. PMID: 19929470 Clinical Trial.

5

Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.

Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Liu L, et al. Clin Cancer Res. 2012 Mar 15;18(6):1751-9. doi: 10.1158/1078-0432.CCR-11-2442. Epub 2012 Jan 24. Clin Cancer Res. 2012. PMID: 22275504 Clinical Trial.

6

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Zhang W, Meng Y, Yang L, Shen M, Zhou L, Li R, Wang Y, Du W, Xiong Y, Han Y, Zhang X, Liu L, Ren X. Zhang W, et al. Cancer Biol Med. 2021 Aug 11;18(4):1109-17. doi: 10.20892/j.issn.2095-3941.2021.0037. Online ahead of print. Cancer Biol Med. 2021. PMID: 34378879 Free PMC article.

7

Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.

Xu H, Feng H, Zhang W, Wei F, Zhou L, Liu L, Zhao Y, Lv Y, Shi X, Zhang J, Ren X. Xu H, et al. Exp Cell Res. 2022 Jul 1;416(1):113157. doi: 10.1016/j.yexcr.2022.113157. Epub 2022 Apr 12. Exp Cell Res. 2022. PMID: 35427598 Free article.

8

Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma.

Cao S, Wang YL, Ren XB, Yu JP, Ren BZ, Zhang XW, Zhang WH, Han Y. Cao S, et al. Among authors: zhang xw, zhang wh. Cancer Biother Radiopharm. 2011 Aug;26(4):503-10. doi: 10.1089/cbr.2011.0982. Epub 2011 Aug 3. Cancer Biother Radiopharm. 2011. PMID: 21812652 Clinical Trial.

9

Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo.

Yu J, Ren X, Cao S, Zhang W, Hao X. Yu J, et al. Cancer Biother Radiopharm. 2006 Jun;21(3):276-84. doi: 10.1089/cbr.2006.21.276. Cancer Biother Radiopharm. 2006. PMID: 16918305

10

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification.

Wang X, Cao J, Du W, Zhang W, Cao S. Wang X, et al. Clin Case Rep. 2021 Jul 23;9(7):e04487. doi: 10.1002/ccr3.4487. eCollection 2021 Jul. Clin Case Rep. 2021. PMID: 34322251 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,470 results

Search Page